1Drilon A, Subbiah V, Gautschi O, et al. Selpercatinib in patients with RET fusion–positive non–small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol. 2023;41(2):385-394. https://doi.org/10.1200/jco.22.00393
2Gautschi O, Drilon A, Solomon B, et al. Final data from phase 1/2 LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small-cell lung cancer. Poster presented at: European Lung Cancer Congress; March 20-23, 2024; Prague, Czech Republic.
3Besse B, Drilon A, Solomon B, et al. Updated overall efficacy and safety of selpercatinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC): LIBRETTO-001 study. Poster presented at: 57th Annual Meeting of the American Society of Clinical Oncology (ASCO Virtual); June 4-8, 2021. Accessed June 17, 2021. https://assets.ctfassets.net/mpejy6umgthp/2f27z1LfWgu72F8XkLYZEF/c1fd8da34b879306f0d39fc81d10515f/ASCO2021_DV0819_BESSE2.pdf
4Loong HH, Goto K, Solomon BJ, et al. Randomized phase III study of first-line selpercatinib versus pembrolizumab and chemotherapy in RET fusion-positive NSCLC. Abstract presented at: 48th Annual Meeting of the European Society for Medical Oncology (ESMO); October 21 2023; Madrid Spain. Accessed October 21, 2023. https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/presentation/list?q=Herbert+Loong&r=st~3
5Zhou C, Solomon BJ, Loong K, et al. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion–positive NSCLC. N Engl J Med. 2023;389(20):1839-1850. https://www.nejm.org/doi/10.1056/NEJMoa2309457
6Data on file, Eli Lilly and Company and/or one of its subsidiaries.
7Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion–positive non–small-cell lung cancer. N Engl J Med. 2020;383(9):813-824. https://dx.doi.org/10.1056/NEJMoa2005653
8Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383(9):825-835. https://dx.doi.org/10.1056/NEJMoa2005651
9Retsevmo [Fachinformation]. Eli Lilly Nederland B.V., Niederlande.
10A study of selpercatinib (LOXO-292) in participants with advanced solid tumors, RET fusion-positive solid tumors, and medullary thyroid cancer (LIBRETTO-001). ClinicalTrials.gov identifier: NCT03157128. Updated March 4, 2024. Accessed March 11, 2024. https://www.clinicaltrials.gov/ct2/show/NCT03157128
11Drilon A, Subbiah V, Gautschi O, et al. Durability of efficacy and safety with selpercatinib in patients with RET fusion+ non-small-cell lung cancer: LIBRETTO-001. Poster presented at European Lung Cancer Congress (ELCC Virtual) 2022; March 30-April 2, 2022.